NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its New […]

(NASDAQ:NVDA), Record revenue of $57.0 billion, up 22% from Q2 and up 62% from a year ago Record Data Center revenue of $51.2 billion, up 25% from Q2 and up 66% from a year ago SANTA CLARA, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) — NVIDIA (NASDAQ: NVDA) today reported record revenue for the third quarter

(NASDAQ:ZVSA),(OTC US:ZVSA),(Other OTC:ZVSA), ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases. The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential

(NASDAQ:VVOS), Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos”

NVIDIA Announces Financial Results for Third Quarter Fiscal 2026 GlobeNewswire November 19, 2025 Record revenue of $57.0 billion, up 22% from Q2 and up 62% from a year ago Record Data Center revenue of $51.2 billion, up 25% from Q2 and up 66% from a year ago SANTA CLARA, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE)

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results GlobeNewswire November 19, 2025 ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases. The lead indication for

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 GlobeNewswire November 19, 2025 Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide

(Other OTC:SFDL),(OTC US:SFDL), AIKEN, S.C., Nov. 19, 2025 (GLOBE NEWSWIRE) — Security Federal Corporation, parent company of Security Federal Bank, is pleased to announce that a quarterly dividend of $0.15 per share will be paid on or about December 15, 2025, to shareholders of record as of November 30, 2025. This is the one hundred

(NASDAQ:PNRG), Houston, Nov. 19, 2025 (GLOBE NEWSWIRE) — PrimeEnergy Resources Corporation (PNRG) (the “Company”) today announced financial and operational results for the quarter ended September 30, 2025, as reported in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Financial Results • Net income was $10.6 million for the quarter and

PRIMEENERGY RESOURCES CORPORATION (PNRG) ANNOUNCES THIRD QUARTER RESULTS GlobeNewswire November 19, 2025 Houston, Nov. 19, 2025 (GLOBE NEWSWIRE) — PrimeEnergy Resources Corporation (PNRG) (the “Company”) today announced financial and operational results for the quarter ended September 30, 2025, as reported in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Financial